Aug 08, 2022 5:00pm EDT

Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

Aug 02, 2022 5:00pm EDT

Medexus Schedules First Quarter 2023 Conference Call

Jul 25, 2022 7:00am EDT

Treosulfan NDA Resubmitted to FDA

Jun 22, 2022 5:50pm EDT

Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History)

Jun 14, 2022 4:30pm EDT

Medexus Schedules Fourth Quarter and Fiscal Year 2022 Conference Call

Jun 06, 2022 8:30am EDT

Treosulfan Pivotal Study Results Published

May 24, 2022 5:05pm EDT

Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

Apr 22, 2022 8:30am EDT

Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

Apr 19, 2022 4:20pm EDT

Medexus to Present at the Bloom Burton & Co. Healthcare Investor Conference

Mar 09, 2022 8:00am EST

Medexus to Participate in the 34th Annual Roth Conference